dalteparin has been researched along with Cerebral Hemorrhage in 28 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Cerebral Hemorrhage: Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of | 5.14 | The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009) |
| "The analyses used data from the Tinzapararin in Acute Ischaemic Stroke Trial, a randomized controlled trial assessing tinzaparin (low molecular weight heparin) versus aspirin in 1484 patients with acute ischemic stroke." | 5.14 | Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. ( Bath, PM; Christensen, H; De Deyn, P; England, TJ; Geeganage, C; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2010) |
| "The hemorrhagic form of cerebral venous thrombosis can be a diagnostic challenge and is treated by anticoagulation therapy, despite the existence of an intracerebral hemorrhage." | 1.62 | Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report. ( Bains, SS; Cardoso, ER; Farkas, J; Robison, B, 2021) |
| "Early pharmacological deep vein thrombosis (DVT) prophylaxis is recommended by guidelines, but rarely started within 48 h." | 1.51 | Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage. ( Addis, A; Ammenwerth, E; Beer, R; Gaasch, M; Hackl, W; Helbok, R; Huber, L; Ianosi, B; Kofler, M; Pfausler, B; Rass, V; Rhomberg, P; Schiefecker, AJ; Thomé, C, 2019) |
| "Aspirin (53." | 1.43 | Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience. ( Fahed, E; Ghauche, J; Maarrawi, J; Menassa-Moussa, L; Moussa, R; Nohra, G; Okais, N; Rahme, R; Rizk, T; Samaha, E, 2016) |
| "LMWH seems to be safe and efficacious for both management and prophylaxis of VTEs in pediatric neurosurgery." | 1.42 | The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients. ( Briceño, V; Fridley, J; Gonda, DD; Jea, A; Lam, SK; Luerssen, TG; Ryan, SL, 2015) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "Incidence, seriousness and causality of maternal, fetal and neonatal adverse events, pregnancy outcome, and incidence of venous thromboembolism." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 15 (53.57) | 29.6817 |
| 2010's | 8 (28.57) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Bellido, M | 1 |
| van der Velden, VH | 1 |
| Leebeek, FW | 1 |
| te Boekhorst, PA | 1 |
| Kay, R | 1 |
| Wong, KS | 1 |
| Yu, YL | 1 |
| Chan, YW | 1 |
| Tsoi, TH | 1 |
| Ahuja, AT | 1 |
| Chan, FL | 1 |
| Fong, KY | 1 |
| Law, CB | 1 |
| Wong, A | 1 |
| Muñoz Morente, A | 1 |
| Barón Ramos, MA | 1 |
| Mateos Fernández, S | 1 |
| López Palmero, S | 1 |
| Villar Jiménez, J | 1 |
| Regueira Iglesias, JM | 1 |
| Paciaroni, M | 1 |
| Agnelli, G | 1 |
| Alberti, A | 1 |
| Becattini, C | 1 |
| Guercini, F | 1 |
| Martini, G | 1 |
| Tassi, R | 1 |
| Marotta, G | 1 |
| Venti, M | 1 |
| Acciarresi, M | 1 |
| Mosconi, MG | 1 |
| Marcheselli, S | 1 |
| Fratticci, L | 1 |
| D'Amore, C | 1 |
| Ageno, W | 1 |
| Versino, M | 1 |
| De Lodovici, ML | 1 |
| Carimati, F | 1 |
| Pezzini, A | 1 |
| Padovani, A | 1 |
| Corea, F | 1 |
| Scoditti, U | 1 |
| Denti, L | 1 |
| Tassinari, T | 1 |
| Silvestrelli, G | 1 |
| Ciccone, A | 1 |
| Caso, V | 1 |
| Cardoso, ER | 1 |
| Bains, SS | 1 |
| Robison, B | 1 |
| Farkas, J | 1 |
| Qian, C | 1 |
| Huhtakangas, J | 1 |
| Juvela, S | 2 |
| Bode, MK | 1 |
| Tatlisumak, T | 1 |
| Savolainen, M | 1 |
| Numminen, H | 1 |
| Ollikainen, J | 1 |
| Luostarinen, L | 1 |
| Kupila, L | 1 |
| Tetri, S | 2 |
| Perry, LA | 1 |
| Berge, E | 1 |
| Bowditch, J | 1 |
| Forfang, E | 1 |
| Rønning, OM | 1 |
| Hankey, GJ | 1 |
| Villanueva, E | 1 |
| Al-Shahi Salman, R | 1 |
| Huang, YC | 1 |
| Wang, JD | 1 |
| Lee, FY | 1 |
| Fu, LS | 1 |
| Ianosi, B | 1 |
| Gaasch, M | 1 |
| Rass, V | 1 |
| Huber, L | 1 |
| Hackl, W | 1 |
| Kofler, M | 1 |
| Schiefecker, AJ | 1 |
| Addis, A | 1 |
| Beer, R | 1 |
| Rhomberg, P | 1 |
| Pfausler, B | 1 |
| Thomé, C | 1 |
| Ammenwerth, E | 1 |
| Helbok, R | 1 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Gonda, DD | 1 |
| Fridley, J | 1 |
| Ryan, SL | 1 |
| Briceño, V | 1 |
| Lam, SK | 1 |
| Luerssen, TG | 1 |
| Jea, A | 1 |
| Fahed, E | 1 |
| Ghauche, J | 1 |
| Rahme, R | 1 |
| Okais, N | 1 |
| Samaha, E | 1 |
| Nohra, G | 1 |
| Rizk, T | 1 |
| Maarrawi, J | 1 |
| Menassa-Moussa, L | 1 |
| Moussa, R | 1 |
| Bertini, G | 1 |
| Perugi, S | 1 |
| Dani, C | 1 |
| Prisco, D | 1 |
| Fonda, C | 1 |
| Varela Rois, P | 1 |
| González García, J | 1 |
| Pérez Rodríguez, MT | 1 |
| Paseiro García, MJ | 1 |
| Carcacía Hermilla, ID | 1 |
| Ali, Z | 1 |
| Prabhakar, H | 1 |
| Rath, GP | 1 |
| Dash, HH | 1 |
| Ibrahim, A | 1 |
| Ashkan, K | 1 |
| Smith, M | 1 |
| Watkins, L | 1 |
| Calvo-Romero, JM | 1 |
| Nessel, CO | 1 |
| Hsiao, MC | 1 |
| Lee, JD | 1 |
| Lee, M | 1 |
| Weng, HH | 1 |
| Hakala, J | 1 |
| Saloheimo, P | 1 |
| Pyhtinen, J | 1 |
| Rusanen, H | 1 |
| Savolainen, ER | 1 |
| Hillbom, M | 1 |
| Dickinson, LD | 1 |
| Miller, LD | 1 |
| Patel, CP | 1 |
| Gupta, SK | 1 |
| Gallus, AS | 1 |
| Oles, D | 1 |
| Berryessa, R | 1 |
| Campbell, K | 1 |
| Bhatti, MA | 1 |
| Lepercq, J | 1 |
| Conard, J | 1 |
| Borel-Derlon, A | 1 |
| Darmon, JY | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Schved, JF | 1 |
| Tournaire, M | 1 |
| Borg, JY | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| Sare, GM | 2 |
| Bath, PM | 3 |
| Gray, LJ | 2 |
| Moulin, T | 2 |
| Woimant, F | 2 |
| England, T | 1 |
| Geeganage, C | 2 |
| Christensen, H | 2 |
| De Deyn, PP | 2 |
| Leys, D | 3 |
| O'Neill, D | 3 |
| Ringelstein, EB | 3 |
| England, TJ | 1 |
| De Deyn, P | 1 |
| Sprigg, N | 1 |
| Lindenstrøm, E | 1 |
| Boysen, G | 1 |
| Friis, P | 1 |
| Marttila, R | 1 |
| Olsson, JE | 1 |
| van der Sande, JJ | 1 |
| Turpie, AG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients[NCT01573169] | Phase 3 | 73 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to The trial has been terminated prematurely after the randomization of 73 patients due to a lack of funding.) | ||
| Phase 1 Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-Like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide in 12 Patients With Recurre[NCT01550523] | Phase 1 | 13 participants (Actual) | Interventional | 2012-02-09 | Completed | ||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
symptomatic and asymptomatic intra and extracranial bleedings (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 1 |
| Standard Therapy | 3 |
"modified Rankin Scale (mRS) equal to and greater than 3.~0 - No symptoms.~- No significant disability. Able to carry out all usual activities, despite some symptoms.~- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.~- Moderate disability. Requires some help, but able to walk unassisted.~- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.~- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.~- Dead." (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 27 |
| Standard Therapy | 30 |
mortality of any cause (NCT01573169)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 7 |
| Standard Therapy | 6 |
Symptomatic venous thromboembolism (deep venous thrombosis and/or pulmonary embolism) and asymptomatic deep venous thrombosis on ultrasound examination (NCT01573169)
Timeframe: 10 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Low Weight Molecular Heparin | 6 |
| Standard Therapy | 7 |
3 reviews available for dalteparin and Cerebral Hemorrhage
| Article | Year |
|---|---|
PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Hemorrhagic Stroke; Humans; Middle Aged; Venous Thr | 2020 |
Antithrombotic treatment after stroke due to intracerebral haemorrhage.
Topics: Cerebral Hemorrhage; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Intracranial Thrombosis; Rand | 2017 |
Preventing venous thromboembolism in general medical inpatients and after an ischaemic stroke.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as | 2000 |
7 trials available for dalteparin and Cerebral Hemorrhage
| Article | Year |
|---|---|
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
Topics: Activities of Daily Living; Acute Disease; Aged; Brain Ischemia; Cerebral Hemorrhage; Cerebral Infar | 1995 |
PREvention of VENous Thromboembolism in Hemorrhagic Stroke Patients - PREVENTIHS Study: A Randomized Controlled Trial and a Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Hemorrhagic Stroke; Humans; Middle Aged; Venous Thr | 2020 |
Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Disease Progression; Double-Blind Meth | 2021 |
Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors.
Topics: Adult; Aged; Anticoagulants; Brain Neoplasms; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Male; | 1998 |
The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
Topics: Acute Disease; Aspirin; Blood Pressure; Brain; Brain Ischemia; Causality; Cerebral Hemorrhage; Comor | 2009 |
Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial.
Topics: Aged; Anticoagulants; Aspirin; Cerebral Hemorrhage; Cerebral Infarction; Dose-Response Relationship, | 2010 |
Stroke severity, early recovery and outcome are each related with clinical classification of stroke: data from the 'Tinzaparin in Acute Ischaemic Stroke Trial' (TAIST).
Topics: Aged; Aged, 80 and over; Brain Infarction; Brain Ischemia; Cerebral Hemorrhage; Disease Progression; | 2007 |
19 other studies available for dalteparin and Cerebral Hemorrhage
| Article | Year |
|---|---|
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
Topics: Adult; Anemia, Aplastic; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Fatal Outcome; Hemoglo | 2012 |
[Anticoagulation with bemiparina after intracerebral hemorrhage as complication of bacterial endocarditis on metallic prosthetic valve].
Topics: Cerebral Hemorrhage; Endocarditis, Bacterial; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; | 2004 |
Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report.
Topics: Anticoagulants; Cerebral Hemorrhage; COVID-19; Enoxaparin; Hematoma; Humans; Intracranial Thrombosis | 2021 |
Pediatric Malignant Atrophic Papulosis.
Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Cerebral Cortex; Cerebral Hemorrhage; Child, Pres | 2018 |
Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage.
Topics: Aged; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Glasgow Coma Scale; Hematoma; Humans; | 2019 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
Topics: Adolescent; Anticoagulants; Cerebral Hemorrhage; Child; Child, Preschool; Drug Administration Schedu | 2015 |
Antithrombotic Medication Use and Misuse Among Patients with Intracranial Hemorrhage: A 16-Year, Lebanese, Single-Center Experience.
Topics: Acenocoumarol; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cerebra | 2016 |
Cerebral venous thrombosis treated with enoxaparin in an IUGR neonate with DIC.
Topics: Anticoagulants; Brain; Cerebral Hemorrhage; Cerebral Veins; Cerebrovascular Disorders; Disseminated | 2009 |
[Subdural spinal hematoma and intraventricular bleeding after lumbar puncture].
Topics: Aged; Anticoagulants; Back Pain; Cerebral Hemorrhage; Cerebral Ventricles; Enoxaparin; Fatal Outcome | 2009 |
Enoxaparin induced intracerebral haemorrhage after deep brain stimulation surgery.
Topics: Aged; Anticoagulants; Cerebral Hemorrhage; Deep Brain Stimulation; Enoxaparin; Humans; Male; Postope | 2009 |
Anticoagulation in a head-injured patient.
Topics: Accidental Falls; Anticoagulants; Brain Injuries; Cerebral Hemorrhage; Contraindications; Enoxaparin | 2003 |
Hemorrhagic transformation of ischemic stroke associated with enoxaparin and aspirin concomitant therapy.
Topics: Acute Disease; Anticoagulants; Aspirin; Cerebral Hemorrhage; Drug Therapy, Combination; Enoxaparin; | 2004 |
On "Current role of antithrombotic agents in the treatment of acute coronary syndromes" (Semin Thromb Hemost 2004;30:627-632).
Topics: Cerebral Hemorrhage; Confounding Factors, Epidemiologic; Enoxaparin; Fibrinolytic Agents; Hemorrhage | 2005 |
Massive pontine hemorrhagic transformation associated with an anticoagulant for basilar artery occlusion.
Topics: Aged; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Humans; Male; Pons; Tomography, X-Ray Compute | 2006 |
Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Drug Administration Schedule; Enoxapar | 2008 |
Emergency redo mitral valve replacement in a 27-year-old pregnant female with a clotted prosthetic mitral valve, preoperative fetal demise and postoperative ventricular assist device: a case report.
Topics: Adult; Anticoagulants; Blood Coagulation; Cardiac Surgical Procedures; Cerebral Hemorrhage; Enoxapar | 2001 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |